NK cells are difficult to cultivate compared to other immune cells. In a conventional method, an average of 200 to 300 million cells are grown in one cultivation. However, NKCL had dramatically increased the number of cells by producing an average of 2 to 4 billion cells.
Each cell cultivation has its own optimal environment needed to effectively grow cells. NKCL has constructed a database of 12 different optimal recipes. resulting in more than 10 times higher culture efficiency.
Even if 2 to 4 billion NK cells are injected, only 10 to 20% reach cancer cells on average.
The reason is that, before reaching the cancer cells, the immune cells are dispersed into curing bad blood and other non-lethal diseases.
NKCL has developed technology to direct more than 70% of NK cells to attack targeted cancer cells, maximizing therapeutic effects.
As with many medicines and cure for diseases, the biggest drawbacks for the treatments are the costs. The existing NK cell practices enables only 3 patients to be treated by one researcher. NKCL developed an AI (Artificial Intelligence) that finds by itself an optimized environment for cell cultivation. With know-how taught to a machine, the productivity has increased by 100 times where one researcher can treat 300 patients. NKCL is promoting popularization and mass-production of NK Cell Treatment.